Seven Fleet Capital Management LP Has $95.66 Million Stake in Tango Therapeutics, Inc. $TNGX

Posted by Francis Steltz on Aug 27th, 2026

Seven Fleet Capital Management LP lifted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) by 302.2% during the second quarter, HoldingsChannel reports. The firm owned 3,228,144 shares of the company’s stock after purchasing an additional 2,425,484 shares during the quarter. Tango Therapeutics accounts for about 15.8% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 2nd biggest holding. Seven Fleet Capital Management LP’s holdings in Tango Therapeutics were worth $95,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP bought a new stake in Tango Therapeutics in the second quarter worth about $35,000. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the 4th quarter valued at approximately $35,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the period. Finally, ANTIPODES PARTNERS Ltd bought a new position in Tango Therapeutics during the fourth quarter valued at $40,000. Institutional investors own 78.99% of the company’s stock.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the transaction, the insider directly owned 115,743 shares in the company, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Stock Performance

NASDAQ:TNGX opened at $25.47 on Thursday. The business’s fifty day moving average is $27.90 and its 200 day moving average is $23.04. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of -29.96 and a beta of 1.16. Tango Therapeutics, Inc. has a 52-week low of $6.25 and a 52-week high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Equities analysts predict that Tango Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on TNGX shares. JPMorgan Chase & Co. started coverage on Tango Therapeutics in a research report on Wednesday, July 15th. They set an “overweight” rating and a $46.00 price target on the stock. Weiss Ratings raised shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Mizuho increased their target price on shares of Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Guggenheim lifted their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen lowered shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.46.

Read Our Latest Research Report on TNGX

Tango Therapeutics Company Profile

(Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.